Market Mover: Ampio (AMPE) Gains at Midday June 21

Equities Staff  |

Ampio Pharmaceuticals Inc (NYSE: AMPE) shares have risen 7.53%, or $0.0122 per share, as on 11:47:04 est today. Since opening the day at $0.16, 4,492,537 shares of Ampio have been traded today and the stock has moved between $0.18 and $0.16.  

Already the company has a YTD change of 71.58%.

Ampio expects its next earnings on 2022-08-03.

For technical charts, analysis, and more on Ampio visit the company profile.

About Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily engaged in the development of AmpionTM, its lead anti-inflammatory drug, which is currently undergoing clinical trials focused on the treatment of patients afflicted with COVID-19 induced acute respiratory distress syndrome (ARDS) as well as patients suffering from severe (KL-4) osteoarthritis of the knee (OAK). Both conditions impact a significant percentage of the population and due to the lack of any FDA approved drugs for treatment, there exists a significant unmet medical need. Ampion is backed by an extensive global patent portfolio with intellectual property protection extending through 2035. In addition, Ampion will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).

To get more information on Ampio Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Ampio Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content